6345-68-2

Usage

Type of compound

Aromatic compound

Contains

a. Bromine (Br)
b. Nitro group (NO2)
c. Phenylmethoxy group (C6H5-O-CH3)

Usage

a. Building block in organic synthesis
b. Intermediate in the production of pharmaceuticals and agrochemicals

Properties

a. Antimicrobial
b. Antiviral

Potential applications

a. Medicinal chemistry

Safety precautions

a. Toxic
b. May cause skin and eye irritation
c. Handle with caution

InChI:InChI=1/C13H10BrNO3/c14-12-7-6-11(15(16)17)8-13(12)18-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 52427-05-1 2-bromo-5-nitrophenol 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 185331-69-5 1-bromo-2-fluoro-4-nitrobenzene 
• 100-51-6 benzyl alcohol 

Downstream Products

• 408352-23-8 bis-(2-benzyloxy-4-nitro-phenyl)-sulfide 
• 408341-03-7 2-benzyloxy-4-nitro-thiophenol 
• 40475-20-5 5,5'-diamino-2,2'-sulfonyl-di-phenol 
• 99971-06-9 5,5'-dinitro-2,2'-sulfanediyl-di-phenol 
• 873394-71-9 5,5'-dinitro-2,2'-sulfonyl-di-phenol 
• 859313-33-0 2-benzyloxy-1-(2-iodo-4-nitro-phenylsulfanyl)-4-nitro-benzene 
• 874506-18-0 bis-(2-benzyloxy-4-nitro-phenyl)-sulfone 
• 127943-83-3 3-(benzyloxy)-4-bromoaniline 

Relevant academic research and scientific papers

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase

The inhibition of 11β-hydroxylase is a promising strategy for the treatment of Cushing's syndrome, in particular for the recurrent and subclinical cases. To achieve proof of concept in rats, efforts were paid to identify novel lead compounds inhibiting both human and rat CYP11B1. Modifications on a potent promiscuous inhibitor of hCYP11B1, hCYP11B2 and hCYP19 (compound IV) that exhibited moderate rCYP11B1 inhibition led to compound 8 as a new promising lead compound. Significant improvements compared to starting point IV were achieved regarding inhibitory potency against both human and rat CYP11B1 (IC50 values of 2 and 163 nM, respectively) as well as selectivity over hCYP19 (IC50 Combining double low line 1900 nM). Accordingly, compound 8 was around 7-and 28-fold more potent than metyrapone regarding the inhibition of human and rat CYP11B1 and exhibited a comparable selectivity over hCYP11B2 (SF of 3.5 vs 4.9). With further optimizations on this new lead compound 8, drug candidates with satisfying profiles are expected to be discovered.